Peripherally Inserted Central Catheter Devices Market Summary

• The PICC Devices market is estimated at USD 1.35 billion in 2025 and is projected to reach USD 2.38 billion by 2034. Growth is anchored in the rising burden of cancer and other chronic diseases requiring long-term intravenous therapy, the shift of infusion care toward outpatient and home settings, and continuous innovation in catheter materials, coatings, and placement technology.
• The global PICC Devices market is growing at a CAGR of 6.5% during the forecast period from 2026 to 2034.
• By product type, the power-injected PICC segment dominated the PICC Devices market with a 58% share in 2025.
• By design, the triple lumen segment dominated the PICC Devices market with a 51% share in 2025.
• By end-user, the hospitals segment dominated the PICC Devices market with a 72% share in 2025.
• North America dominated the global PICC Devices market revenue with a 46% share in 2025, representing the highest regional market share globally.

A peripherally inserted central catheter (PICC) is a long, flexible, thin-walled catheter inserted through a peripheral vein, typically in the upper arm, and advanced until its tip rests in a large central vein near the heart, usually the lower third of the superior vena cava. PICC devices provide reliable, medium- to long-term central venous access for the administration of chemotherapy, long-term intravenous antibiotics, parenteral nutrition, and other irritant or vesicant therapies, and for frequent blood sampling, while avoiding the risks of direct central venous puncture of the neck or chest. Devices are offered as power-injected (pressure-injectable) catheters, which are rated to withstand high-pressure contrast injection for CT imaging, and as non-power-injected or conventional catheters, in single-, double-, and triple-lumen designs, and increasingly incorporate antimicrobial, antithrombogenic, or hydrophilic materials, valved or open-ended tips, and compatibility with ECG-based tip confirmation. The market is organized by product type across power-injected and non-power injected/conventional PICCs; by design across single-, double-, and triple-lumen catheters; by end-user across hospitals, ambulatory surgical centers, and others, including home care settings and specialty infusion centers; and by geography. Driven by the rising burden of cancer and chronic disease, the migration of infusion therapy to outpatient and home settings, and sustained product innovation aimed at lowering infection and thrombosis rates, PICC devices have become a core component of the global vascular access market.

PICC Devices Market Key Growth Drivers

• The rising global cancer burden is expanding demand for chemotherapy and supportive infusion therapy delivered through central venous access, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.
• The growing prevalence of chronic and infectious diseases, including renal disease, diabetes, and serious infections requiring prolonged intravenous antibiotics, is increasing the number of patients who need reliable long-term venous access.
• The shift of infusion therapy toward outpatient, home care, and ambulatory settings favors PICCs, which can be placed at the bedside and remain in place for weeks to months.
• Technological advancements, including antimicrobial and antithrombogenic materials, power injectable designs, valved tips, and ECG-based tip location, are improving safety and widening clinical use.
• A strong clinical focus on preventing catheter-related bloodstream infection, thrombosis, and occlusion is driving adoption of next-generation devices, including the anti-thrombogenic indication cleared by the FDA for Access Vascular's HydroPICC in 2026.
• Expanding vascular access teams and nurse-led bedside placement programs are broadening procedural capacity and supporting steady PICC utilization in hospitals.
• The convergence of cancer burden, chronic disease prevalence, outpatient care migration, and material innovation is expected to sustain steady growth in the market through 2034.

Key Companies in PICC Devices Market

The competitive landscape is led by the following active manufacturers:

• B. Braun Melsungen AG
• AngioDynamics
• Cardinal Health
• BD
• Teleflex Incorporated
• Argon Medical
• Cook Group
• ICU Medical Inc.
• Medical Components Inc.
• Access Vascular

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

PICC Devices Market Size

The following snapshot summarizes the principal report metrics for the PICC Devices market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the PICC Devices Market

Market Drivers

Rising Global Cancer Burden and Chemotherapy Demand

The most powerful driver of the PICC Devices market is the rising global cancer burden and the corresponding growth in chemotherapy and supportive infusion therapy. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050. Many cytotoxic regimens, vesicant drugs, and prolonged treatment courses require central venous access, and PICCs offer oncology teams a reliable, minimally invasive route that can be placed at the bedside and maintained across multiple treatment cycles. Power injected PICCs add further value by allowing contrast-enhanced CT imaging through the same line, reducing repeated needle sticks for patients who undergo frequent staging scans. As cancer incidence, survival, and treatment duration all increase, demand for dependable long-term central access expands directly, anchoring market growth through 2034.

Increasing Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic and infectious diseases is broadening the patient population that needs central venous access. Patients with chronic kidney disease, diabetes-related infections, osteomyelitis, endocarditis, and other serious infections frequently require weeks of intravenous antibiotics, while those with gastrointestinal failure or malnutrition depend on parenteral nutrition. Ageing populations in North America, Europe, and Asia-Pacific add to this base, as older patients tend to have more comorbidities and more fragile peripheral veins. PICCs provide a practical alternative to repeated peripheral cannulation and to tunneled or non-tunneled central lines placed through the chest or neck, which supports their use across acute care, post-acute, and home settings. This sustained clinical need translates directly into recurring demand for PICC devices across the forecast period.

Shift Toward Outpatient, Home Infusion, and Ambulatory Care

A structural shift of infusion therapy from inpatient wards to outpatient clinics, ambulatory centers, and the home is a central growth engine for the market. Health systems and payers are encouraging earlier discharge and lower-cost sites of care, and patients who need weeks of intravenous therapy can often complete treatment at home when reliable central access is in place. PICCs suit this model because they can be inserted at the bedside by trained nurses, do not require an operating room, and remain in place for extended periods. Growth in home infusion services, specialty infusion pharmacies, and ambulatory surgical centers therefore broadens the end-user base beyond hospitals and increases the volume of catheters placed outside the traditional acute-care setting, reinforcing demand throughout the forecast period.

Technological Advancements in Catheter Design and Materials

Continuous innovation in catheter design and materials is improving safety and expanding clinical use. Manufacturers are developing antimicrobial and antithrombogenic coatings, hydrophilic and hydrogel biomaterials, valved and open-ended tips, smaller-diameter and multi-lumen designs, and power-injectable constructions rated for high-pressure contrast delivery. Placement technology is advancing in parallel, with ECG-based tip confirmation and ultrasound guidance enabling accurate bedside placement. In June 2026, the FDA cleared a new anti-thrombogenic indication for Access Vascular's single- and dual-lumen HydroPICC catheters and its HydroMid catheter, illustrating how material science is becoming a differentiator in a category long anchored in polyurethane-based devices. These advances reduce complications, support longer dwell times, and give clinicians reasons to adopt premium catheters, supporting both volume and value growth.

Focus on Infection Prevention and Nurse-Led Bedside Placement

Healthcare systems are placing growing emphasis on preventing catheter-related bloodstream infection, thrombosis, and occlusion, which add cost, prolong hospital stays, and affect patient outcomes. This focus is encouraging evidence-based device selection, standardized insertion bundles, and investment in dedicated vascular access teams that place PICCs at the bedside using real-time ultrasound and tip-confirmation tools. Group purchasing organizations and integrated delivery networks increasingly evaluate catheters on complication rates and total cost of care rather than unit price alone, which rewards manufacturers able to demonstrate lower infection and thrombosis rates. As vascular access programs mature and quality metrics tighten, demand for advanced, clinically differentiated PICC devices is expected to strengthen across the forecast period.

Expanding Demand for Power Injected and Multi-Lumen Access in Imaging and Critical Care

Demand for power-injected and multi-lumen PICCs is rising as hospitals seek a single line that can handle several clinical needs. Power-injected PICCs allow contrast-enhanced CT and other imaging procedures to be performed through the existing catheter, reducing the need for additional peripheral intravenous access in oncology and critical care patients. Multi-lumen designs allow clinicians to infuse incompatible medications, parenteral nutrition, blood products, and vasoactive drugs simultaneously while keeping a lumen available for sampling. These capabilities are particularly valuable in intensive care, oncology, and complex medical-surgical populations, where patients receive many concurrent therapies. As care complexity increases and hospitals standardize on versatile, multi-purpose access devices, adoption of power-injected and multi-lumen PICCs continues to expand.

Strategic Partnerships, Portfolio Moves, and Commercial Expansion by Manufacturers

Manufacturers are actively reshaping portfolios and distribution relationships to strengthen their positions in vascular access. In June 2026, Access Vascular and Medline announced a multi-year agreement to roll out co-branded HydroPICC and HydroMid catheters through Medline's procedure kits across more than 1,600 Prime Vendor customers, with products expected from late 2026. Teleflex has been concentrating its portfolio around vascular access and interventional businesses, completing the sale of its OEM business for USD 1.5 billion in August 2026, and was awarded a national group purchasing agreement by Premier covering central venous access products effective July 1, 2026. Vygon acquired the Stiletto extended-dwell catheter and SlipStream technology from Avia Vascular in February 2026. These moves expand commercial reach, bring new technologies to market, and intensify competition around differentiated catheter platforms.

Market Restraints

Despite steady momentum, the PICC Devices market faces material constraints. Catheter-related complications remain the most significant clinical challenge, as catheter-related bloodstream infection, deep vein thrombosis, and catheter occlusion can lead to line removal, additional treatment, longer hospital stays, and higher costs, and have made some clinicians cautious about PICC use in patients with limited venous access or elevated thrombotic risk. Product recalls and safety communications add further pressure; in March 2025, BD issued an urgent recall of certain 4 Fr single lumen PowerPICC and PowerPICC SOLO catheters after reports of material fatigue leaks, and the FDA issued an early alert on the issue, highlighting the scrutiny that material and manufacturing quality attract. Competition from alternative access devices, including midline catheters, implanted ports, tunneled central lines, and extended-dwell peripheral catheters, can limit PICC uptake in selected patient groups. Reimbursement constraints and pricing pressure from group purchasing organizations and integrated delivery networks compress margins, while the cost of premium antimicrobial or biomaterial-based catheters can slow adoption in cost-sensitive health systems. A shortage of trained vascular access nurses and clinicians, variable adherence to insertion and maintenance protocols, and stringent regulatory requirements across the United States, Europe, Japan, and China further constrain growth, and trade policy changes and tariffs on medical device inputs introduce additional sourcing and cost uncertainty. Together, these clinical, regulatory, economic, and workforce barriers temper the pace of growth, even as the underlying drivers of cancer burden, chronic disease prevalence, and outpatient care migration remain firmly intact.

PICC Devices Market Segment Analysis

The PICC Devices Market is segmented by product type (power injected peripherally inserted catheters, non-power injected/conventional peripherally inserted central catheters), design (single lumen, double lumen, triple lumen), end-user (hospitals, ambulatory surgical centers, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Product Type

Dominant Subsegment: Power Injected PICCs. 

The power-injected PICC segment accounted for 58% of the PICC Devices market in 2025. Power-injected PICCs are the leading product type because they combine standard central venous access with the ability to withstand high-pressure contrast injection for CT imaging, allowing a single line to serve infusion therapy, blood sampling, and diagnostic imaging. Oncology and critical care teams value this versatility, since patients who undergo frequent staging scans can avoid repeated peripheral intravenous placement. Manufacturers have also shifted their premium portfolios toward power injected platforms with antimicrobial or antithrombogenic features, valved tips, and compatibility with ECG-based tip location, which supports higher average selling prices and strong institutional standardization. Hospitals and group purchasing organizations increasingly specify power injectable capability as the default for new contracts. While non-power injected or conventional PICCs remain widely used for cost-sensitive and routine infusion needs, particularly in home care, long-term care, and price-sensitive regions, the clinical flexibility, premium positioning, and growing evidence base of power injected catheters secure the segment's leadership across the forecast period.

By Design

Dominant Subsegment: Triple Lumen PICCs. 

The triple lumen segment accounted for 51% of the PICC Devices market in 2025. Triple lumen PICCs are the leading design because they allow clinicians to administer several infusions at once, including incompatible medications, parenteral nutrition, blood products, and vasoactive drugs, while keeping a dedicated lumen free for blood sampling or monitoring. This capability is particularly valuable in intensive care, oncology, and complex medical-surgical populations, where patients receive many concurrent therapies and venous access is limited. Multi-lumen catheters also reduce the need for additional lines, which can save vein sites and nursing time. Single lumen catheters remain widely used for straightforward therapy and are favored where minimizing catheter diameter and infection and thrombosis risk is the priority, while double lumen catheters offer a balance of function and size across general hospital use. Higher lumen counts are associated with larger catheter bodies and greater complication risk, which is encouraging innovation in smaller, biomaterial-based multi-lumen designs. Nonetheless, the clinical versatility and the complexity of patients treated in hospitals keep triple lumen PICCs the dominant design across the forecast period.

By End-User

Dominant Subsegment: Hospitals. 

The hospitals segment accounted for 72% of the PICC Devices market in 2025. Hospitals are the leading end-user because they treat the largest share of patients who require central venous access, including those in oncology, critical care, surgery, infectious disease, and nephrology, and because they host the vascular access teams, ultrasound and tip-confirmation equipment, and imaging facilities needed for safe PICC placement. Most PICCs are inserted during inpatient stays or at hospital-based outpatient infusion centers, and hospital purchasing is concentrated through group purchasing organizations and integrated delivery networks that award multi-year contracts to leading manufacturers. Ambulatory surgical centers and other settings, including home infusion providers, specialty infusion centers, and long-term care facilities, are growing as care migrates to lower-cost sites and as more patients complete intravenous therapy at home. Even so, the breadth of clinical indications, the volume of catheters placed, and the infrastructure advantages of acute care settings secure hospitals' clear leadership across the forecast period.

PICC Devices Market Region Analysis

Dominant Region: North America

North America accounted for 46% of the global PICC Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a well-developed healthcare infrastructure, a high burden of cancer and chronic disease, widespread use of vascular access teams and bedside PICC placement, and early adoption of power-injected and advanced-material catheters, particularly in the United States. North America is home to the leading PICC manufacturers, including BD, Teleflex, AngioDynamics, and Access Vascular, and to large group purchasing organizations and integrated delivery networks that influence device selection at scale. Established reimbursement for vascular access procedures, strong home infusion infrastructure, and a high concentration of cancer centers support sustained utilization. Ongoing innovation in antimicrobial, antithrombogenic, and biomaterial-based catheters, together with distribution partnerships such as the 2026 Access Vascular and Medline agreement, anchors the region's continued leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the PICC Devices market. The region's elevated CAGR is driven by rising cancer incidence, expanding hospital and oncology infrastructure, a growing elderly population, and increasing healthcare investment across China, Japan, India, South Korea, and Australia. Greater awareness of long-term intravenous therapy, growing adoption of nurse-led PICC placement programs, and improving access to advanced catheter technologies are accelerating adoption, while multinational manufacturers and regional players expand their distribution networks and local manufacturing. Rising medical tourism, expanding insurance coverage, and government investment in cancer care and hospital capacity further widen the addressable patient base. The combination of high disease burden, healthcare infrastructure build-out, and increasing clinical acceptance positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 46% of the global PICC Devices market revenue in 2025. The United States dominates on the strength of its healthcare infrastructure, high procedure volumes, established vascular access teams, and early adoption of power-injected and advanced-material catheters, while Canada and Mexico contribute growing demand as oncology and home infusion capacity expands.

Europe

Europe is a large and advanced regional market, supported by established healthcare systems, a high burden of cancer and age-related disease, and growing use of nurse-led PICC insertion programs. Clinical guidelines emphasizing infection prevention, the requirements of the EU Medical Device Regulation, and the presence of manufacturers such as B. Braun and Vygon shape device selection across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising cancer incidence, expanding hospital and oncology infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Increasing adoption of PICCs for chemotherapy and long-term infusion, together with expanding local manufacturing and distribution, is accelerating regional growth.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding hospital infrastructure, rising cancer and chronic disease burden, and gradually improving access to central venous access devices are broadening demand, while price sensitivity, uneven reimbursement, and limited trained vascular access personnel moderate the pace of adoption.

PICC Devices Market Competitive Landscape

The PICC Devices market is classified as Moderately Concentrated. A group of established vascular access manufacturers with broad portfolios and strong hospital and group purchasing relationships, including BD, Teleflex, AngioDynamics, and B. Braun, anchors the top tier, while ICU Medical, Cardinal Health, Cook Group, Argon Medical, Medical Components, and innovation-focused entrants such as Access Vascular compete through product differentiation, advanced biomaterials, distribution partnerships, and targeted clinical evidence, increasing competition in the premium power injected and multi-lumen segments.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with a handful of large vascular access manufacturers leading and a field of specialized and innovation-focused competitors.
• Leading players: BD, Teleflex, AngioDynamics, and B. Braun anchor the top tier through broad vascular access portfolios and entrenched hospital relationships.
• Geographic reach: Leaders operate global manufacturing and distribution networks and sell through hospitals, integrated delivery networks, group purchasing organizations, and distribution partners.
• Product portfolio strength: Top players offer single, double, and triple lumen PICCs in power-injected and conventional formats, alongside midlines, central venous catheters, ports, and tip-location and securement accessories.
• Technology differentiation: Antimicrobial and antithrombogenic coatings, hydrogel and other advanced biomaterials, valved tips, and ECG-based tip confirmation are decisive competitive advantages.
• Strategic partnerships: Distribution and co-development agreements, such as Access Vascular's 2026 agreement with Medline and Teleflex's 2026 Premier group purchasing agreement for central venous access products, extend commercial reach.
• M&A and portfolio activity: Active portfolio reshaping, including Teleflex's divestitures of its OEM, Acute Care, and Interventional Urology businesses to focus on vascular and interventional care, and Vygon's 2026 acquisition of the Stiletto extended-dwell catheter platform.
• Quality and regulatory track record: Material quality, recall history, and regulatory compliance, as highlighted by the 2025 BD PowerPICC recall, influence hospital purchasing and supplier standing.
• Innovation focus: Anti-thrombogenic and low-infection materials, smaller-profile multi-lumen designs, integrated tip location, and extended-dwell and remote-monitoring concepts.

PICC Devices Market Recent Developmental Activities

In August 2026, Teleflex Incorporated completed the divestiture of its OEM business to Montagu and Kohlberg for USD 1.5 billion in cash, with the separate sale of its Acute Care and Interventional Urology businesses to Intersurgical for approximately USD 530 million anticipated to close in the fourth quarter of 2026. Strategic significance: Sharpens Teleflex's focus on its vascular access and interventional portfolio, including the Arrow PICC franchise.

In July 2026, Teleflex Incorporated began a national group purchasing agreement with Premier, Inc., effective July 1, 2026, covering select central venous access products for Premier members. Strategic significance: Strengthens contract access to a large base of U.S. hospitals for Teleflex's vascular access portfolio.

In June 2026, Access Vascular, Inc., announced a multi-year agreement with Medline to roll out co-branded HydroPICC and HydroMid catheters, expected to be available through Medline from late 2026 in fully assembled procedure kits across its more than 1,600 Prime Vendor customers. Strategic significance: Gives an innovation-focused manufacturer national distribution scale and accelerates adoption of hydrogel-based catheters.

In June 2026, Access Vascular, Inc., received FDA clearance of a new anti-thrombogenic indication for its single-lumen HydroMid and its single- and dual-lumen HydroPICC catheter lines. Strategic significance: Provides a clinical differentiator against conventional polyurethane catheters in a category with limited recent innovation.

In June 2026, Vygon received Health Canada approval to commercialize Stiletto, a new generation of extended-dwell catheters integrating SlipStream technology. Strategic significance: Expands the extended-dwell catheter options that compete with PICCs and midlines in selected patient groups.

In February 2026, Vygon announced its acquisition of Stiletto and its SlipStream technology from Avia Vascular. Strategic significance: Adds a differentiated extended-dwell catheter platform to Vygon's vascular access portfolio.

In March 2025, BD (Becton, Dickinson and Company), through its Bard Access Systems subsidiary, issued an urgent medical device product recall for certain 4 Fr single lumen PowerPICC and PowerPICC SOLO catheters due to material fatigue leaks, and the FDA issued an early alert on the issue in April 2025. Strategic significance: Underscores the importance of materials and manufacturing quality in power-injected PICCs and heightens purchaser scrutiny of supplier quality.

PICC Devices Market Segmentation

PICC Devices Market by Product Type

• Power Injected Peripherally Inserted Catheters
• Non-Power Injected/Conventional Peripherally Inserted Central Catheters

PICC Devices Market by Design

• Single Lumen
• Double Lumen
• Triple Lumen

PICC Devices Market by End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

PICC Devices Market by Geography

• North America PICC Devices Market

• United States PICC Devices Market Size in USD million (2023-2034)
• Canada PICC Devices Market Size in USD million (2023-2034)
• Mexico PICC Devices Market Size in USD million (2023-2034)
• Europe PICC Devices Market
• Germany PICC Devices Market Size in USD million (2023-2034)
• United Kingdom PICC Devices Market Size in USD million (2023-2034)
• France PICC Devices Market Size in USD million (2023-2034)
• Italy PICC Devices Market Size in USD million (2023-2034)
• Spain PICC Devices Market Size in USD million (2023-2034)
• Rest of Europe PICC Devices Market Size in USD million (2023-2034)
• Asia-Pacific PICC Devices Market
• China PICC Devices Market Size in USD million (2023-2034)
• Japan PICC Devices Market Size in USD million (2023-2034)
• India PICC Devices Market Size in USD million (2023-2034)
• Australia PICC Devices Market Size in USD million (2023-2034)
• South Korea PICC Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific PICC Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) PICC Devices Market
• Middle East PICC Devices Market Size in USD million (2023-2034)
• Africa PICC Devices Market Size in USD million (2023-2034)
• South America PICC Devices Market Size in USD million (2023-2034)

PICC Devices Market Recent Industry Trends and Milestones (2023-2026)

PICC Devices Market Startup Funding and Investment Trends

Investment in the PICC Devices ecosystem has concentrated on differentiated catheter materials, extended-dwell access technologies, and strategic distribution partnerships. The following companies illustrate recent investment and strategic activity and technology focus.

Capital and strategic activity are flowing toward manufacturers that can demonstrate lower complication rates and secure hospital distribution. Teleflex's USD 2.0 billion in announced divestitures reflect a deliberate focus on vascular and interventional care; Vygon's February 2026 acquisition of the Stiletto platform adds an extended-dwell option to its portfolio, and the 2026 agreement between Access Vascular and Medline brings an innovation-focused manufacturer national distribution scale. Established players such as BD, B. Braun, AngioDynamics, ICU Medical, and Cardinal Health continue to invest in portfolio breadth and quality, while specialized entrants compete on materials and clinical evidence. Collectively, these activities signal conviction that anti-thrombogenic and low-infection materials, power injection and multi-lumen versatility, and integrated distribution will define the next phase of competitive advantage in the global PICC Devices market.

Key Takeaways from the PICC Devices Market Report Study

• Market size analysis for the current PICC devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global PICC devices market.
• Various opportunities available for competitors in the PICC devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current PICC devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for PICC devices market growth in the future?

Target audience who can benefit from this PICC devices market report study 

• PICC devices product providers
• Research organizations and consulting companies
• PICC devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in PICC devices
• Various end-users who want to know more about the PICC devices market and the latest technological developments in the PICC devices market.